Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails

Executive Summary

CDER's Woodcock suggests exclusivity rules outdated for abuse-deterrent technology development, and Rep. Griffith takes it to mean legal changes are needed.


Related Content

Opioids: Senate Wants Mandatory Prescriber Training; Can FDA Make It Work?
US Healthcare Bill's Failure Could Have Unpleasant Ripple Effects For Pharma
User Fees: Should US FDA Incur Penalties For Missed Deadlines?
Abuse-Deterrent Opioids: US FDA Follows The ‘Route Of Abuse’ To Exclusivity
Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity
Abuse-Deterrent Opioids: FDA Advocates Joint Brand-Generic Development Plan
FDA Panel Nod For Egalet Opioid's Deterrence Claims Made Easier By Tablet Hardness
When Is An Abuse-Deterrent Claim FDA Approved?
Opioids: FDA Asks If Abuse-Deterrence Incentives Are In Line
Opioid Abuse Deterrence: FDA Development Ideas Are Out Of This World


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts